Chronic lymphocytic leukemia
Chronic lymphocytic leukemia
This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whether there is a need for more aggressive management.
In Section I, Dr. Terry Hamblin addresses the nature of the disease, accurate diagnostic procedures, evidence for an early "preclinical" phase, the use of newer prognostic features to distinguish who will be likely to progress or not, and whether it is best to watch or treat early stage disease.
In Section II, Dr. Neil Kay and colleagues address the biologic aspects of the disease and how they may relate to disease progression. Review of the newer insights into gene expression, recurring genetic defects, role of cytokines/autocrine pathways, and the interaction of the CLL B cell with the microenvironment are emphasized. The relationship of these events to both trigger disease progression and as opportunities for future therapeutic intervention even in early stage disease is also considered.
In Section III, Dr. John Byrd and colleagues review the historical and now current approaches to management of the previously untreated progressive B-CLL patient. They discuss what decision tree could be used in the initial decision to treat a given patient. The use of single agents versus newer combination approaches such as chemoimmunotherapy are discussed here. In addition, the place of marrow transplant and some of the newer antibodies available for treatment of B-CLL are considered. Finally, a challenge to utilize our growing knowledge of the biology of B-CLL in the early stage B-CLL is proffered.
193-213
Kay, Neil E.
355b77f7-a2ed-42ba-bef7-3fd2bb2cef88
Hamblin, Terry J.
57389613-7900-48fd-b3e6-8ca8fbdceccb
Jelinek, Diane F.
56658f3d-3143-4661-b76f-9ecb91c0c859
Dewald, Gordon W.
0d096653-a2d5-4357-bc59-f5e110ba00e5
Byrd, John C.
0e651550-7666-40d2-b1b3-260297d11018
Farag, Sherif
b51430b4-1ac6-4c9d-abfb-7bbfae8d00f5
Lucas, Margaret
7938fdb7-14b8-4999-9fdd-94bf2d93e3f0
Lin, Thomas
b1160c72-d2db-460b-a4e3-64cc314d6ebf
2002
Kay, Neil E.
355b77f7-a2ed-42ba-bef7-3fd2bb2cef88
Hamblin, Terry J.
57389613-7900-48fd-b3e6-8ca8fbdceccb
Jelinek, Diane F.
56658f3d-3143-4661-b76f-9ecb91c0c859
Dewald, Gordon W.
0d096653-a2d5-4357-bc59-f5e110ba00e5
Byrd, John C.
0e651550-7666-40d2-b1b3-260297d11018
Farag, Sherif
b51430b4-1ac6-4c9d-abfb-7bbfae8d00f5
Lucas, Margaret
7938fdb7-14b8-4999-9fdd-94bf2d93e3f0
Lin, Thomas
b1160c72-d2db-460b-a4e3-64cc314d6ebf
Kay, Neil E., Hamblin, Terry J., Jelinek, Diane F., Dewald, Gordon W., Byrd, John C., Farag, Sherif, Lucas, Margaret and Lin, Thomas
(2002)
Chronic lymphocytic leukemia.
Hematology, ASH Education Program, .
Abstract
This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whether there is a need for more aggressive management.
In Section I, Dr. Terry Hamblin addresses the nature of the disease, accurate diagnostic procedures, evidence for an early "preclinical" phase, the use of newer prognostic features to distinguish who will be likely to progress or not, and whether it is best to watch or treat early stage disease.
In Section II, Dr. Neil Kay and colleagues address the biologic aspects of the disease and how they may relate to disease progression. Review of the newer insights into gene expression, recurring genetic defects, role of cytokines/autocrine pathways, and the interaction of the CLL B cell with the microenvironment are emphasized. The relationship of these events to both trigger disease progression and as opportunities for future therapeutic intervention even in early stage disease is also considered.
In Section III, Dr. John Byrd and colleagues review the historical and now current approaches to management of the previously untreated progressive B-CLL patient. They discuss what decision tree could be used in the initial decision to treat a given patient. The use of single agents versus newer combination approaches such as chemoimmunotherapy are discussed here. In addition, the place of marrow transplant and some of the newer antibodies available for treatment of B-CLL are considered. Finally, a challenge to utilize our growing knowledge of the biology of B-CLL in the early stage B-CLL is proffered.
This record has no associated files available for download.
More information
Published date: 2002
Identifiers
Local EPrints ID: 26420
URI: http://eprints.soton.ac.uk/id/eprint/26420
ISSN: 1520-4391
PURE UUID: d77c6d8e-37cb-4ea9-84fa-ba2b766cd997
Catalogue record
Date deposited: 21 Apr 2006
Last modified: 22 Jul 2022 20:34
Export record
Contributors
Author:
Neil E. Kay
Author:
Terry J. Hamblin
Author:
Diane F. Jelinek
Author:
Gordon W. Dewald
Author:
John C. Byrd
Author:
Sherif Farag
Author:
Margaret Lucas
Author:
Thomas Lin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics